Estimating Healthcare Costs of Acute Gastroenteritis and Human Campylobacteriosis in Switzerland

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 2016 Aug 12

PMID 27513710

Citations 10

Authors

C Schmutz

D Mausezahl

P J Bless

C Hatz

M Schwenkglenks

D Urbinello

Affiliations

Soon will be listed here.

Abstract

Rising numbers of campylobacteriosis case notifications in Switzerland resulted in an increased attention to acute gastroenteritis (AG) in general. Patients with a laboratory-confirmed Campylobacter infection perceive their disease as severe and around 15% of these patients are hospitalized. This study aimed at estimating healthcare costs due to AG and campylobacteriosis in Switzerland. We used official health statistics, data from different studies and expert opinion for estimating individual treatment costs for patients with different illness severity and for extrapolating overall costs due to AG and campylobacteriosis. We estimated that total Swiss healthcare costs resulting from these diseases amount to €29-45 million annually. Data suggest that patients with AG consulting a physician without a stool diagnostic test account for €9·0-24·2 million, patients with a negative stool test result for Campylobacter spp. for €12·3 million, patients testing positive for Campylobacter spp. for €1·8 million and hospitalized campylobacteriosis patients for €6·5 million/year. Healthcare costs of campylobacteriosis are high and most likely increasing in Switzerland considering that campylobacteriosis case notifications steadily increased in the past decade. Costs and potential cost savings for the healthcare system should be considered when designing sectorial and cross-sectorial interventions to reduce the burden of human campylobacteriosis in Switzerland.

Citing Articles

Economic Burden of Acute Gastroenteritis among Members of Integrated Healthcare Delivery System, United States, 2014-2016.

Dickerson J, Salas S, Donald J, Groom H, Lee M, Mattison C Emerg Infect Dis. 2024; 30(5):968-973.

PMID: 38666613 PMC: 11060443. DOI: 10.3201/eid3005.230356.

Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis.

Schorling E, Lick S, Steinberg P, Bruggemann D PLoS One. 2023; 18(4):e0283865.

PMID: 37018288 PMC: 10075411. DOI: 10.1371/journal.pone.0283865.

Quantitative Microbial Risk Assessment for in Ground Meat Products in Korea.

Lee J, Lee H, Lee S, Kim S, Ha J, Choi Y Food Sci Anim Resour. 2019; 39(4):565-575.

PMID: 31508587 PMC: 6728815. DOI: 10.5851/kosfa.2019.e39.

The health and economic impact of acute gastroenteritis in Belgium, 2010-2014.

Papadopoulos T, Klamer S, Jacquinet S, Catry B, Litzroth A, Mortgat L Epidemiol Infect. 2019; 147:e146.

PMID: 30869061 PMC: 6518509. DOI: 10.1017/S095026881900044X.

Clinical impact of the type VI secretion system on virulence of Campylobacter species during infection.

Agnetti J, Seth-Smith H, Ursich S, Reist J, Basler M, Nickel C BMC Infect Dis. 2019; 19(1):237.

PMID: 30845966 PMC: 6407262. DOI: 10.1186/s12879-019-3858-x.

References

Bless P, Schmutz C, Suter K, Jost M, Hattendorf J, Mausezahl-Feuz M . A tradition and an epidemic: determinants of the campylobacteriosis winter peak in Switzerland. Eur J Epidemiol. 2014; 29(7):527-37. PMC: 4099532. DOI: 10.1007/s10654-014-9917-0. View

Majowicz S, McNab W, Sockett P, Henson T, Dore K, Edge V . Burden and cost of gastroenteritis in a Canadian community. J Food Prot. 2006; 69(3):651-9. DOI: 10.4315/0362-028x-69.3.651. View

Van Den Brandhof W, de Wit G, de Wit M, van Duynhoven Y . Costs of gastroenteritis in The Netherlands. Epidemiol Infect. 2004; 132(2):211-21. PMC: 2870096. DOI: 10.1017/s0950268803001559. View

Havelaar A, van Pelt W, Ang C, Wagenaar J, van Putten J, Gross U . Immunity to Campylobacter: its role in risk assessment and epidemiology. Crit Rev Microbiol. 2009; 35(1):1-22. DOI: 10.1080/10408410802636017. View

Scallan E, Hoekstra R, Angulo F, Tauxe R, Widdowson M, Roy S . Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis. 2011; 17(1):7-15. PMC: 3375761. DOI: 10.3201/eid1701.p11101. View

Gibbons C, Mangen M, Plass D, Havelaar A, Brooke R, Kramarz P . Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 2014; 14:147. PMC: 4015559. DOI: 10.1186/1471-2458-14-147. View

Lindqvist R, Andersson Y, Lindback J, Wegscheider M, Eriksson Y, Tidestrom L . A one-year study of foodborne illnesses in the municipality of Uppsala, Sweden. Emerg Infect Dis. 2001; 7(3 Suppl):588-92. PMC: 2631855. DOI: 10.3201/eid0707.010742. View

Hellard M, Sinclair M, Harris A, Kirk M, Fairley C . Cost of community gastroenteritis. J Gastroenterol Hepatol. 2003; 18(3):322-8. DOI: 10.1046/j.1440-1746.2003.02959.x. View

Gellynck X, Messens W, Halet D, Grijspeerdt K, Hartnett E, Viaene J . Economics of reducing Campylobacter at different levels within the Belgian poultry meat chain. J Food Prot. 2008; 71(3):479-85. DOI: 10.4315/0362-028x-71.3.479. View

10.

Scallan E, Jones T, Cronquist A, Thomas S, Frenzen P, Hoefer D . Factors associated with seeking medical care and submitting a stool sample in estimating the burden of foodborne illness. Foodborne Pathog Dis. 2007; 3(4):432-8. DOI: 10.1089/fpd.2006.3.432. View

11.

Havelaar A, Ivarsson S, Lofdahl M, Nauta M . Estimating the true incidence of campylobacteriosis and salmonellosis in the European Union, 2009. Epidemiol Infect. 2012; 141(2):293-302. PMC: 9152072. DOI: 10.1017/S0950268812000568. View

12.

Friesema I, Lugner A, van Duynhoven Y . Costs of gastroenteritis in the Netherlands, with special attention for severe cases. Eur J Clin Microbiol Infect Dis. 2012; 31(8):1895-900. DOI: 10.1007/s10096-011-1518-1. View

13.

Hall G, Kirk M, Becker N, Gregory J, Unicomb L, Millard G . Estimating foodborne gastroenteritis, Australia. Emerg Infect Dis. 2005; 11(8):1257-64. PMC: 3320479. DOI: 10.3201/eid1108.041367. View

14.

Hennessy T, Marcus R, Deneen V, Reddy S, Vugia D, Townes J . Survey of physician diagnostic practices for patients with acute diarrhea: clinical and public health implications. Clin Infect Dis. 2004; 38 Suppl 3:S203-11. DOI: 10.1086/381588. View

15.

Buzby J, Allos B, Roberts T . The economic burden of Campylobacter-associated Guillain-Barré syndrome. J Infect Dis. 1997; 176 Suppl 2:S192-7. DOI: 10.1086/513785. View

16.

Schmutz C, Mausezahl D, Jost M, Baumgartner A, Mausezahl-Feuz M . Inverse trends of Campylobacter and Salmonella in Swiss surveillance data, 1988-2013. Euro Surveill. 2016; 21(6). DOI: 10.2807/1560-7917.ES.2016.21.6.30130. View

17.

Karve S, Krishnarajah G, Korsnes J, Cassidy A, Candrilli S . Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother. 2014; 10(6):1544-56. PMC: 5396247. DOI: 10.4161/hv.28704. View

18.

Tam C, Rodrigues L, Viviani L, Dodds J, Evans M, Hunter P . Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut. 2011; 61(1):69-77. PMC: 3230829. DOI: 10.1136/gut.2011.238386. View

19.

Mangen M, Bouwknegt M, Friesema I, Haagsma J, Kortbeek L, Tariq L . Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2014; 196:84-93. DOI: 10.1016/j.ijfoodmicro.2014.11.022. View

20.

Brinkhof M, Spoerri A, Birrer A, Hagman R, Koch D, Zwahlen M . Influenza-attributable mortality among the elderly in Switzerland. Swiss Med Wkly. 2006; 136(19-20):302-9. DOI: 10.4414/smw.2006.11373. View